Haleon (LON: HLN) (NYSE: HLN) was a deeply unsatisfactory demerger from GlazoSmithKline back near a year. Yes, the price has recently risen above the IPO one but that's only after a significant slump. It is possible though now for there to be room for further significant growth. Note that this is not a certainty, rather it's that one of the issues which could have been depressing the price - or which could limit rises even - has now been dealt with.
The issue was that after the demerger Glaxo still retained a substantial stake in Haleon. Glaxo also said that they were going to sell that stake at some convenient point. When there's an overhang of equity of course there's a certain reluctance to push the price higher. For higher prices are likely to be met with sales from that stock of shares which it has already been announced are available to sell.
Glaxo has now announced that it has sold out of its Haleon position. There is no longer therefore that overhang. HLN shares are free to move higher. As we say, this doesn't mean that Haleon will move higher, it just removes an issue that might have been depressing the price.
Haleon share price from London Stock ExchangeThere is another issue that has also been depressing the Haleon price and that's the Zantac litigation. It seems an odd thing to worry about as Haleon didn't sell Zantac. But there are class action suits in process on the idea that ranitidine did produce certain cancers. If that's true then there could be compensation to pay. Given the success of Zantac that would be a substantial sum. So, the cases are important.
It's also true that for any compensation costs to reach Haleon it would be necessary for any awards to burn through both Glazo and Pfizer which seems like an unlikely idea. But it is worth recalling that absolutely anyone to do with asbestos has indeed been driven bankrupt by litigation. So, while it's most unlikely, it is possible, that Haleon shareholders could be on the hook here. Glaxo also had an announcement about that. The Canadian case has now been thrown out. Given the absurdity to which the American plaintiffs system can soar that's not entirely cut and dried. But it is indicative of how things are likely to go.
Two of the issues which have generally been thought to depress the Haleon share price are now dealt with. Whether HLN will now move higher is another matter but weights are off the shoulders there.



